The form was uploaded to medical-data-models.org - Original URL: https://medical-data-models.org/16703
StudyName: New Anticancer Treatment, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485  NCT00373425
Date of export from the portal: 02.07.2020
Date of Upload / last change: 01.08.2016
License: Creative Commons BY 4.0

----

Description: 
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425
Part of study: New Anticancer Treatment
